【摘要】 在许多肿瘤组织中均有表皮生长因子受体(epidermal growthfactor receptor,EGFR)的过表达,它的失调与肿瘤对化疗和放疗的耐受以及不良预后相关,为肿瘤的治疗提供了一个理想的分子靶点.Cetuximab(C225)是特异性EGFR单克隆抗体,与化疗或放疗联合应用时具有协同作用,具有毒副作用少、靶向性好等优点.Cetuximab(C225)已被批准用于对伊利替康抵抗的结直肠癌和头颈部鳞癌的治疗,对非小细胞肺癌、乳腺癌、胰腺癌等具有EGFR高表达肿瘤治疗的临床试验正在进行之中,为肿瘤治疗开辟了一个全新的领域.更多还原

【Abstract】 The epidermal growth factor receptor (EGFR) provides a rational target for cancer therapy as it is commonly overexpressed in a variety of solid tumors, and its deregulation is correlated with resistance to chemotherapy and radiotherapy and a poor prognosis. Cetuximab (C255), a specific monoclonal antibody directed against EGFR, is synergistic with chemotherapy and radiotherapy and has been licensed for the treatment of irinotecan refractory colorectal cancer (CRC) and squamous cell cancer of the head and neck (SCCHN), which express EGFR. In addition, the clinical trials about cetuximab for the treatment of non-small cell lung cancer (NSCLC), breast and pancreas carcinoma are ongoing, and cetuximab has been proven to a novel strategy for the treatment of cancer with the overexpression of EGFR.更多还原